About Concert AI
Concert AI is a Healthcare company based in Boston (United States) founded in 2018 by Romesh Wadhwani. AI platform for oncology research and data is utilized. It operates in the Healthcare and Technology sectors. Concert AI has raised $300 million across 2 funding rounds from investors including SymphonyAI, Sixth Street and Maverick Ventures. The company has 848 employees. Concert AI has completed 1 acquisition, including CancerLinQ. Concert AI was last valued at $1.9 billion in December 2025. Its chief executive, as recorded, is Jeff Elton. Its website concertai.com draws about 42 thousand monthly visits. Its Indian entity Symphony Concerto India Private Limited reported revenue of ₹155 Cr. Concert AI offers products and services including Digital Trial Solution, Clinical Trial Optimization, TeraRecon Advanced Visualization, Eureka Clinical AI, and CancerLinQ. Its focus areas include HealthTech, Life Sciences Tech, Diversified and Life Sciences. Its competitors include Veeva Systems, Definitive Healthcare and ESO; 3 of its 3 listed competitors have raised funding.
Company details
Concert AI was founded in 2018 and is based in Boston, United States. An AI-based platform is operated for oncology research, encompassing data on lab results, practice visits, tumor observations, vitals, pain biometrics, medications, diagnosis states, budgets, costs, and comorbidities. Real-time patient matching to clinical trials is facilitated, alongside collaborations with biopharma companies in the sector.
- Headquarters Boston, United States
- Employees 848
- Founders Romesh Wadhwani
- Stage Unicorn
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website concertai.com
- Social LinkedIn X
- Legal Name Symphony Concerto India Private Limited
- Date of Incorporation 06 Nov, 2019
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹155 Cr
FY 2025 · +6% YoY
- Indian entity net profit₹14.57 Cr
FY 2025 · 9% margin
- Indian entity EBITDA₹21.97 Cr
FY 2025 · 14% margin
- Total Equity Funding$300M (USD)
in 2 rounds
- Latest Funding Round$150M (USD), Series C
Mar 2022
- InvestorsSymphonyAI
& 5 more
- Employee Count848
- Investments & Acquisitions
Associated legal entities of Concert AI
Concert AI operates through Symphony Concerto India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Symphony Concerto India Private Limited CIN U72900KA2019PTC129350 | Active | 06 Nov 2019 | Bangalore, Karnataka | ₹155 Cr | 550 | 3 | View details |
Products & Services of Concert AI
Concert AI offers a comprehensive portfolio of products and services, including Digital Trial Solution, Clinical Trial Optimization, TeraRecon Advanced Visualization, Eureka Clinical AI, and CancerLinQ.
Platform for accelerating oncology clinical trials using AI.
Services to enhance trial data analysis and patient outcomes.
Tool for advanced medical imaging and data interpretation.
AI system for clinical insights in oncology research.
Platform aggregating oncology data for research purposes.
Funding Insights of Concert AI
Concert AI has successfully raised a total of $300M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $300M
- Total Rounds 2
- Last Round Series C — $150M
- First Round $150M
(Jan 2020)
- Investors Count 6
All 2 funding rounds of Concert AI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $150M | Series C | $1.9B | Sixth Street | – |
| Jan 2020 | $150M | Series B | – | Declaration Partners |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2022 | $1.9B | •••••••• |
Last known valuation $1.9B (Dec 2025). 6 investors in total: 6 institutional.
Investors in Concert AI
Concert AI has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include SymphonyAI, Sixth Street and Maverick Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and debt investments are managed across multiple sectors. | sixthstreet.com | San Francisco, United States | ||
Early-stage tech and life-sciences firms are funded across the US. | maverickventures.com | San Francisco, United States | ||
| allianceberstein.com | ||||
AI and SaaS-based solutions for digital transformation | 2017 | symphonyai.com | Palo Alto, United States | |
Manages private equity, real estate, and investment strategies for institutional partners. | 2016 | declarationpartners.com | New York, United States | |
SAIGroup is engaged in investing in enterprise AI solutions. | saigroup.ai | Palo Alto, United States |
Investor details for Concert AI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Symphony Concerto India Private Limited (Concert AI)
Symphony Concerto India Private Limited is the primary company behind Concert AI. The board of Symphony Concerto India Private Limited currently have 3 directors; the longest-serving is Chandramouli Panchapakesha Vaidyanathan, appointed in 2019. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Chandramouli Panchapakesha Vaidyanathan DIN 05216587 | Director | 06 Nov 2019 | 6 yrs 11 mo | Symphony Concerto India Private Limited |
| Ravindra Thadimarri DIN 01213505 | Director | 01 Jul 2024 | 2 yrs 3 mo | Symphony Concerto India Private Limited |
| Dileep Kumar Thippireddy DIN 11055201 | Additional Director | 16 Apr 2025 | 1 yr 6 mo | Symphony Concerto India Private Limited |
People of Concert AI
204 people are tracked at Concert AI (64 in leadership, 140 in team); the tracked headcount is 848.
| Name | Role | Group |
|---|---|---|
Jeff Elton | CEO | Leadership |
Romesh Wadhwani | Founder | Leadership |
Dnb Dr. Abhishek Tibrewal M.D., Apgdp-Ra | Director - Clinical Research Informatics | Leadership |
Michael Myshrall | Chief Financial Officer (cfo) | Life Sciences | Generative & Agentic Artificial Intelligence AI | Leadership |
Chirag Shah | Director - Business Analytics, Commercial Solutions | Leadership |
Nick Summers | Vice President Operations | Leadership |
Brendan Gates | Director, Client Success | Leadership |
Shaalan Beg M.D. Fasco | Chief Medical Officer | Leadership |
Claudio D’Ambrosio | Chief Revenue Officer | Leadership |
Hannah Swavely | Director Business Analytics | Leadership |
Matthew Hall | Director, Translational Services | Leadership |
Christine Brannan | Associate Director, Operations | Leadership |
Vishal Akki | Director | Leadership |
Ned Bement | Vice President, Sales - Patient Solutions | Leadership |
Claire Sullivan Gerety | Sr. Director, Sales Operations | Leadership |
Pamela Milo | Senior Director, Privacy And Compliance | Leadership |
Ruth Pe Benito | Vp, Program Head Uro-oncology RWE And Customer Success | Leadership |
Mahnoush Haririfar | Vice President, Strategic Partnerships (vector Oncology Was Acquired By Concertai) | Leadership |
Linda McIlhinney | Senior Director, Integration | Leadership |
Maria Monberg | Director, Precision Oncology | Leadership |
184 more people are available in the full profile.
Complete people profiles for Concert AI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Concert AI
Figures of Symphony Concerto India Private Limited, the primary company behind Concert AI, for FY 2025. Revenue was ₹155 Cr (+6% year on year). Net profit was ₹14.57 Cr (9% margin). EBITDA was ₹21.97 Cr (14% margin). Revenue has grown at a compounded annual rate of +29% over three years.
- ₹155 CrRevenue · FY 2025 · +6% YoY
- ₹14.57 CrNet profit · 9% margin
- ₹21.97 CrEBITDA · 14% margin
- ₹1 LakhPaid-up capital
- 550Employees (provident fund records)
- +29%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Symphony Concerto India Private Limited are on its company page.
Detailed financial statements for Concert AI
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Concert AI
Concert AI has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CancerLinQ.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cancer professionals and researchers are connected through a data platform. | cancerlinq.org | Alexandria, United States | 2011 | Dec 2023 | •••• |
Complete acquisition details for Concert AI
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Concert AI
5 dated milestones of Concert AI across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Concert AI is founded.
- Funding First funding round of $150.0M.
- Funding Latest funding round, Series C, of $150.0M.
- Milestone Reaches Unicorn status.
- Acquisition Acquires CancerLinQ.
Competitors of Concert AI
Concert AI has 3 listed competitors in our database, 3 of them funded. They include Veeva Systems, Definitive Healthcare and ESO.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| veeva.com | 2007 | Pleasanton, United States | $4M | 226 | Cloud-based data management solutions for healthcare are provided. | |
| definitivehc.com | 2008 | Natick, United States | $4.31M | 575 | Offers market intelligence and data analytics for healthcare providers and physicians | |
| eso.com | 2004 | Austin, United States | $50.4M | EHR platform for emergency services is provided. |
Detailed competitors of Concert AI
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Concert AI
The website of Concert AI (concertai.com) receives about 42K visits a month and ranks #555,443 among all websites worldwide, #581 in Biotechnology and Pharmaceuticals.
- Monthly visits42K
▼ 13% vs previous month
- Unique visitors10.4K
per month
- Global rank#555,443
among all websites
- Category rank#581
Health · Biotechnology and Pharmaceuticals
- Bounce rate20%
- Pages per visit5.4
- Average visit8 min 46 sec
- DevicesDesktop 68% · Mobile 32%
Websites whose visitors overlap most with Concert AI. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
drugdiscoverytrends.com | drugdiscoverytrends.com | 100% | #491,427 | – | |
| sofpromed.com | 100% | #1,692,305 | View details | ||
| advarra.com | 100% | 102.4K | #325,515 | View details | |
| allucent.com | 100% | 34.5K | #991,439 | View details | |
ijpsonline.com | ijpsonline.com | 76% | #907,151 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Concert AI
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Concert AI (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Concert Ai
Complete news archive for Concert AI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concert AI
Concert AI was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Concert AI is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jeff Elton is the CEO of Concert AI, as recorded in our data.
Concert AI is a funded company, having raised a total of $300M across 2 funding rounds to date. The company's 1st funding round was a Series B of $150M, raised on Jan 2020.
Concert AI has 848 employees.
The primary company behind Concert AI, Symphony Concerto India Private Limited, reported revenue of ₹155 Cr for FY 2025, up 6% year on year.
Concert AI was founded in 2018 and is based in Boston, United States. An AI-based platform is operated for oncology research, encompassing data on lab results, practice visits, tumor observations, vitals, pain biometrics, medications, diagnosis states, budgets, costs, and comorbidities. Real-time patient matching to clinical trials is facilitated, alongside collaborations with biopharma companies in the sector.
Concert AI's top competitors include Veeva Systems, Definitive Healthcare and ESO.
Concert AI offers Digital Trial Solution, Clinical Trial Optimization, TeraRecon Advanced Visualization, Eureka Clinical AI, and CancerLinQ.
Concert AI has made 1 acquisition, including CancerLinQ.
Concert AI has 6 investors. Key investors include SymphonyAI, Sixth Street, Maverick Ventures, AllianceBernstein, and Declaration Partners.
The valuation of Concert AI is $1.9B as of Dec 2025.